Browse the evidence

Lifestyle modification can provide glycemic benefits to prevent type 2 diabetes (T2D) and its comorbidities.

Practitioners should encourage lifestyle modifications as a standard approach to prevent T2D.

Soy isoflavones can significantly contribute to lowering metabolic risk and affect hormonal balance in women with PCOS.

Incorporating soy isoflavones may be beneficial for women with PCOS in managing metabolic and hormonal issues.

All patients had complete diabetes remission at 12 months, maintained at 24 months.

Laparoscopic sleeve gastrectomy can lead to significant diabetes remission in obese patients, which is important for treatment planning.

Weight-reducing anti-diabetic agents and anti-obesity medications can effectively address both obesity and type 2 diabetes mellitus (T2DM).

Practitioners should consider using these combined strategies for better management of patients with obesity and T2DM.

Utilizing a combination of weight-reducing anti-diabetic agents, anti-obesity medications, and surgical procedures can lead to better clinical outcomes in patients with obesity and T2DM.

Combining different treatment modalities may enhance patient outcomes in managing obesity and T2DM.

The intervention resulted in a decrease in body weight, body mass index, waist circumference, blood pressure, and lipid metabolism parameters.

Health professionals can expect improvements in key health metrics when implementing similar interventions.

GLP-1RAs promote weight loss and improve metabolic health.

GLP-1RAs can be utilized to aid in weight management and metabolic health improvement.

The combination of Cinnamomum cassia (300 mg) and Withania somnifera (150 mg) induced significant weight loss compared to placebo (−2.66% vs. −1.28%, respectively; p = 0.0002).

Practitioners may consider this combination as a low-cost supplement option for enhancing weight loss in overweight and obese patients.

Obesity is associated with serious health risks and consequences for individuals who are pregnant or want to be pregnant.

Healthcare providers should be aware of the risks obesity poses to pregnant individuals.

Lifestyle interventions, such as adherence to a Mediterranean diet and weight loss, have proven beneficial for both metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF).

Encouraging patients to adopt a Mediterranean diet and focus on weight loss can be beneficial for managing both MASLD and HFpEF.

Obesity is a major contributor to type 2 diabetes, necessitating medication management for both conditions.

Addressing obesity is crucial in managing type 2 diabetes, and medication may be necessary.

A weight loss of 10% can already achieve a reduction in cardiovascular endpoints.

Practitioners should aim for at least a 10% weight loss in patients to improve cardiovascular health.

Bariatric interventions have shown the best therapeutic benefits in individuals with obesity.

Bariatric interventions should be considered as a primary treatment option for obesity.

Exenatide combined with Metformin significantly reduced insulin resistance (HOMA-IR) by a mean difference of -0.9 (p < 0.001).

Practitioners may consider the combination of Exenatide and Metformin as an effective treatment for improving insulin resistance in women with PCOS.

Exenatide combined with Metformin reduced body mass index (BMI) by a mean difference of -0.4 (p = 0.03).

The combination therapy may assist in weight management for women with PCOS.

All secondary cardiometabolic outcomes improved significantly throughout the study.

Practitioners can consider compounded GLP-1 ± GIP agonists as effective for improving various cardiometabolic risk factors.

Intensive lifestyle modification and medications that improve insulin resistance are key strategies for preventing type 2 diabetes (T2D).

Practitioners should focus on lifestyle changes and medications to prevent T2D.

Lifestyle measures such as increasing physical activity and improving diet are considered the basis of any drug therapy for dyslipidemias.

Practitioners should prioritize lifestyle interventions in managing dyslipidemias.

Meal replacements (MRs) lead to a significant reduction in fasting blood sugar (FBS) by 3.10 mg/dL.

Incorporating meal replacements can effectively lower fasting blood sugar levels.

The new glycemia targeted specialized supplement (GTSS) produced a 25% reduction in the incremental area under the curve (iAUC) of postprandial blood glucose (PPG) compared to a standardized breakfast.

Using GTSS as a breakfast replacement may help lower postprandial blood glucose levels in patients with type 2 diabetes.

Chronic data generally indicate that supersets and traditional resistance training lead to similar adaptations for endurance, hypertrophy, power, and strength.

Both training modalities can be used interchangeably for long-term adaptations.

Training-induced changes in leg lean body mass and leg press 1RM increased after training with no differences between rBLG and whey groups.

Both rBLG and whey can effectively support muscle gains from resistance training.

There is a relationship between the consumption of ultra processed foods and the prevalence of non-communicable chronic diseases such as obesity, hypertension, and cancer.

Awareness of the health risks associated with ultra processed foods is crucial for public health initiatives.

Evidence of individual response variation can lead to improved exercise prescription.

Practitioners can tailor exercise programs based on individual responses to training.